Psyence Biomedical Ltd. Warrant (PBMWW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Psyence Biomedical Ltd. Warrant (PBMWW) trades at $0.03. Psyence Biomedical Ltd. Warrant is a biotechnology company focused on developing botanical psilocybin-based psychedelic medicines. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for PBMWW: PBMWW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PBMWW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PBMWW: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Psyence Biomedical Ltd. Warrant (PBMWW) Healthcare & Pipeline Overview
Psyence Biomedical Ltd. Warrant, a subsidiary of Psyence Group Inc., is a biotechnology firm developing botanical psilocybin-based medicines, with a focus on addressing anxiety and depression through its PEX010 Phase IIb clinical trial, targeting palliative care and related ailments within the evolving psychedelic medicine landscape.
What Is the Investment Thesis for PBMWW?
Psyence Biomedical Ltd. Warrant presents a speculative investment opportunity within the emerging psychedelic medicine sector. The primary value driver is the successful development and commercialization of PEX010, its lead product candidate currently in Phase IIb clinical trials. Positive clinical trial results and regulatory approvals could significantly increase the company's valuation. The company's focus on palliative care provides a niche market entry point. However, the investment is subject to significant risks, including clinical trial failures, regulatory hurdles, and competition from other companies in the psychedelic medicine space. The company's current market capitalization is $0.00B, and its negative P/E ratio of -6.18 reflects its current lack of profitability. The company's beta of 0.36 suggests lower volatility compared to the overall market. The absence of a dividend reflects the company's focus on reinvesting capital into research and development. Successful completion of Phase IIb trials and subsequent progression through regulatory approval pathways are critical catalysts. The company's financial performance and stock value are highly dependent on the success of PEX010.
Based on FMP financials and quantitative analysis
PBMWW Key Highlights
Lead product candidate PEX010 is in Phase IIb clinical study, targeting anxiety and depression.
- Partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy.
- Focus on treating adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.
- Market Cap of $0.00B reflects the early stage of the company.
- P/E ratio of -6.18 indicates current lack of profitability.
Who Are PBMWW's Competitors?
PBMWW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CMPS COMPASS Pathways plc | $13.82 | -1.36% | $1.86B | 48 |
| MNMD Mind Medicine (MindMed) Inc. | $20.69 | +0.44% | $1.56B | 46 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $7.42 | +0.82% | $2.75B | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PBMWW's Key Strengths?
Focus on botanical psilocybin provides a natural source.
- PEX010 in Phase IIb clinical trials demonstrates progress.
- Partnership with iNGENu Pty Ltd strengthens research capabilities.
- Targeting palliative care offers a niche market entry.
What Are PBMWW's Weaknesses?
Early-stage company with limited revenue.
- Reliance on successful clinical trial outcomes.
- High regulatory hurdles for psychedelic medicines.
- Dependence on external funding for research and development.
What Could Drive PBMWW Stock Higher?
Completion of Phase IIb clinical trials for PEX010.
- Publication of clinical trial results in peer-reviewed journals.
- Regulatory submissions for PEX010 in key markets.
- Increasing acceptance of psychedelic therapies by regulatory agencies.
- Growing awareness of the potential benefits of psilocybin for mental health.
What Are the Key Risks for PBMWW?
Clinical trial failures could delay or halt development.
- Regulatory setbacks could prevent commercialization.
- Competition from other companies in the psychedelic medicine space.
- Negative public perception of psychedelics.
- Dependence on external funding for research and development.
What Are the Growth Opportunities for PBMWW?
- Expansion of PEX010 into new indications: Beyond anxiety and depression in palliative care, PEX010 could be explored for treating other mental health conditions such as PTSD and grief. Timeline: 3-5 years, pending clinical trial results and regulatory approvals.
- Geographic expansion: Initially focused on North America, Psyence Biomedical could expand its clinical trials and commercialization efforts to Europe and other regions where psychedelic therapies are gaining acceptance. The European market represents a significant growth opportunity, with increasing regulatory interest in psychedelic medicine. Timeline: 2-4 years, contingent on regulatory changes and market access.
- Development of new psilocybin-based therapies: Psyence Biomedical could leverage its expertise in botanical psilocybin to develop new formulations and delivery methods, potentially improving the efficacy and patient experience of its therapies. This could involve exploring novel drug delivery systems or combination therapies. Timeline: 4-6 years, dependent on research and development progress.
- Strategic partnerships and collaborations: Collaborating with other companies in the pharmaceutical and biotechnology industries could accelerate the development and commercialization of Psyence Biomedical's products. This could involve partnerships for clinical trials, manufacturing, or distribution. Timeline: Ongoing, dependent on identifying suitable partners.
- Securing regulatory approvals: Obtaining regulatory approvals for PEX010 and other products is crucial for commercial success. This involves navigating complex regulatory pathways in different jurisdictions, including the FDA in the United States and the EMA in Europe. Successful regulatory approvals would open up significant market opportunities. Timeline: 2-5 years, contingent on clinical trial outcomes and regulatory review processes.
What Are PBMWW's Competitive Advantages?
- Proprietary formulations of botanical psilocybin.
- Clinical trial data demonstrating efficacy and safety.
- Intellectual property protection through patents.
- Partnerships with research institutions and healthcare providers.
What Does PBMWW Do?
Psyence Biomedical Ltd. Warrant is a biotechnology company dedicated to the research and development of botanical psilocybin-based psychedelic medicines. The company is focused on addressing mental health disorders, particularly anxiety and depression, within the context of palliative care. Its lead product candidate, PEX010, is a capsule containing naturally sourced psilocybin, currently undergoing Phase IIb clinical trials. PEX010 is being evaluated for its potential to treat anxiety, depression, post-traumatic stress disorder, stress, grief, and adjustment disorder, especially in patients with incurable cancer diagnoses. Psyence Biomedical operates as a subsidiary of Psyence Group Inc. and is based in Toronto, Canada. The company's research and development efforts are centered around harnessing the therapeutic potential of psilocybin, a naturally occurring psychedelic compound found in certain species of mushrooms. Psyence Biomedical is actively involved in clinical trials to assess the safety and efficacy of its psilocybin-based treatments. The partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder due to incurable cancer highlights the company's commitment to rigorous scientific evaluation. The company aims to provide innovative solutions for patients facing mental health challenges, particularly in palliative care settings where conventional treatments may be insufficient. Psyence Biomedical is positioning itself to be a key player in the emerging field of psychedelic medicine, with a focus on botanical psilocybin-based therapies.
What Products and Services Does PBMWW Offer?
- Develop botanical psilocybin-based psychedelic medicines.
- Evaluate natural psilocybin for treating adjustment disorder in palliative care.
- Conduct Phase IIb clinical trials for PEX010, a psilocybin capsule.
- Target anxiety, depression, PTSD, stress, and grief with PEX010.
- Partner with iNGENu Pty Ltd for clinical trials.
- Focus on patients with incurable cancer diagnoses.
How Does PBMWW Make Money?
- Develop and patent psilocybin-based pharmaceutical products.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approvals for commercialization.
- Potentially license or partner for manufacturing and distribution.
What Industry Does PBMWW Operate In?
Psyence Biomedical Ltd. Warrant operates within the rapidly evolving biotechnology and psychedelic medicine industries. The market for psychedelic-assisted therapies is projected to grow significantly, driven by increasing acceptance of psychedelics for mental health treatment and growing clinical evidence supporting their efficacy. The competitive landscape includes other companies developing psychedelic therapies, as well as established pharmaceutical companies offering traditional mental health treatments. Psyence Biomedical's focus on botanical psilocybin and its emphasis on palliative care differentiate it from some competitors. The company's success will depend on its ability to navigate regulatory hurdles, secure funding, and demonstrate the clinical efficacy of its products.
Who Are PBMWW's Key Customers?
- Patients with anxiety and depression.
- Patients in palliative care settings.
- Healthcare providers prescribing mental health treatments.
- Hospitals and clinics offering psychedelic-assisted therapies.
Company Profile
Psyence Biomedical Ltd. Warrant operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Jody Aufrichtig. PBMWW has traded publicly since 2024.
PBMWW Financials
Bull Case vs Bear Case
Bull Case
- Focus on botanical psilocybin provides a natural source.
- PEX010 in Phase IIb clinical trials demonstrates progress.
- Partnership with iNGENu Pty Ltd strengthens research capabilities.
- Targeting palliative care offers a niche market entry.
Bear Case
- Early-stage company with limited revenue.
- Reliance on successful clinical trial outcomes.
- High regulatory hurdles for psychedelic medicines.
- Dependence on external funding for research and development.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PBMWW Latest News
No recent news available for PBMWW.
PBMWW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PBMWW.
Price Targets
Wall Street price target analysis for PBMWW.
PBMWW MoonshotScore
What does this score mean?
The MoonshotScore rates PBMWW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jody Aufrichtig
CEO
Information on Jody Aufrichtig's background is not available within the provided context. Further research would be needed to provide a comprehensive biography, including career history, education, previous roles, and credentials.
Track Record: Information on Jody Aufrichtig's track record is not available within the provided context. Further research would be needed to provide details on key achievements, strategic decisions, and company milestones under their leadership.
Psyence Biomedical Ltd. Warrant Healthcare Stock: Key Questions Answered
What does Psyence Biomedical Ltd. Warrant do?
Psyence Biomedical Ltd. Warrant is a biotechnology company focused on developing botanical psilocybin-based psychedelic medicines. Its primary focus is on addressing mental health disorders, specifically anxiety and depression, particularly in the context of palliative care. The company's lead product candidate, PEX010, is a capsule containing naturally sourced psilocybin, currently undergoing Phase IIb clinical trials.
What do analysts say about PBMWW stock?
There is currently no available analyst coverage or consensus on Psyence Biomedical Ltd. Warrant (PBMWW) due to its early stage and limited market capitalization. As a development-stage biotechnology company focused on psychedelic medicine, the stock's performance is highly dependent on the success of its clinical trials, particularly the Phase IIb trial for PEX010.
What are the main risks for PBMWW?
The main risks for Psyence Biomedical Ltd. Warrant (PBMWW) are inherent to its stage of development and the regulatory landscape of psychedelic medicine. Clinical trial failures represent a significant risk, as negative results could halt the development of PEX010 and other pipeline candidates. Regulatory setbacks, including delays or denials of approval, could also impede commercialization efforts.
What are the key factors to evaluate for PBMWW?
Evaluate PBMWW on fundamentals, analyst consensus, and risk factors. Psyence Biomedical Ltd. Warrant presents a speculative investment opportunity within the emerging psychedelic medicine sector. Not financial advice.
How frequently does PBMWW data refresh on this page?
PBMWW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PBMWW's recent stock price performance?
Psyence Biomedical Ltd. Warrant (PBMWW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on botanical psilocybin provides a natural source. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PBMWW overvalued or undervalued right now?
Psyence Biomedical Ltd. Warrant (PBMWW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PBMWW before investing?
Before investing in Psyence Biomedical Ltd. Warrant (PBMWW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited source data.
- AI analysis pending.